Letrozole

Spezifikationen

112809-51-5CAS-Nummer

675-034-8EG-Nummer

4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrileIUPAC-Name

C17H11N5Chemische Formel

285.3 g/molMolekulargewicht

letrozole; 112809-51-5; Femara; Letrozol; CGS 20267; CGS-20267; Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-; DTXSID4023202; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; CGS20267; NSC-759652; 7LKK855W8I; 4-[(4-CYANOPHENYL)(1H-1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE; CHEBI:6413; DTXCID503202; NSC719345; KISQALI FEMARA CO-PACK COMPONENT LETROZOLE; letrozolum; 4-((4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl)benzonitrile; 4-((4-cyanophenyl)(1H-1,2,4-triazol-1-yl)methyl)benzonitrile; Letrozole Tablets; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); RefChem:55460; L02BG04; 4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile; 675-034-8; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; C17H11N5; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; CHEMBL1444; NCGC00016973-01; Letoval; CAS-112809-51-5; SMR000466343; Femara (TN); LETRAZOLE; HSDB 7461; SR-01000759382; 4,4'-[(1H-1,2,4-Triazol-1-yl)methylene]dibenzonitrile; Letrozole (JAN/USP/INN); UNII-7LKK855W8I; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; CCRIS 8822; Letrozole?; Letrozole CRS; FEM-345; Femara, Letrozole; Letrozole [USAN:USP:INN:BAN]; Letrozole (Standard); 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; LETROZOLE [INN]; LETROZOLE [JAN]; LETROZOLE [MI]; LETROZOLE [HSDB]; LETROZOLE [USAN]; Prestwick0_001025; Prestwick1_001025; Prestwick2_001025; Prestwick3_001025; Femara (TN) (Novartis); LETROZOLE [MART.]; LETROZOLE [USP-RS]; LETROZOLE [WHO-DD]; SCHEMBL4331; 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; BIDD:PXR0130; BSPBio_001209; MLS000759455; MLS001424038; MLS002584991; MLS006010040; BIDD:GT0015; Letrozole - Bio-X trade mark; SPBio_003070; BPBio1_001331; GTPL5209; orb1308084; LETROZOLE [EP IMPURITY]; LETROZOLE [ORANGE BOOK]; LETROZOLE [EP MONOGRAPH]; Letrozole, >=98% (HPLC); BDBM13061; EX-A965; LETROZOLE [USP MONOGRAPH]; GLXC-05072; HMS1571M11; HMS2051E08; HMS2089L22; HMS2098M11; HMS2233C23; HMS3369E11; HMS3393E08; HMS3651K05; HMS3715M11; HMS5079O19; Pharmakon1600-01502354; IVB71296; MSK10362; Tox21_110719; Tox21_303572; EBC-04408; HY-14248R; MFCD00866241; NSC759652; s1235; AKOS005145822; AB07525; AC-1193; CCG-100849; CS-1776; DB01006; FL24873; KS-1269; NC00099; NSC 759652; NSC-719345; NCGC00016973-02; NCGC00016973-03; NCGC00016973-06; NCGC00016973-19; NCGC00257460-01; BL164620; HY-14248; 1-Bis(4-cyanophenyl)methyl-1,2,4-triazole; 4,2,4-Triazol-1-ylmethylene)dibenzonitrile; AB00514009; L1878; NS00000663; SW197294-4; C08163; D00964; EN300-264820; AB00514009-05; AB00514009-07; AB00514009-08; AB00514009-09; AB00514009_10; AB00514009_11; F036495; Q194974; W-60273; 4,4'-(1,2,4-Triazol-1-ylmethylene)dibenzonitrile; Q-201291; SR-01000759382-4; SR-01000759382-5; BRD-K88789588-001-03-2; BRD-K88789588-001-14-9; 4,4 -(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; F2173-0288; Z1741968261; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)bis[benzonitrile]; Letrozole, European Pharmacopoeia (EP) Reference Standard; Letrozole, United States Pharmacopeia (USP) Reference Standard; 4-[1-(4-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE; Letrozole, Pharmaceutical Secondary Standard; Certified Reference Material; CGS 20267; Femara; Lerozole; Letrazole; 4,4'-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile; Letrozole MicronizedSynonyme